Manufacturer
F. HOFFMANN-LA ROCHE LTD(SWITZERLAND)

Registraction Number
MAL24096026ARZ


Content:
Lunsumio 1mg/ml Concentrate for Solution for Infusion contains 1 mg of mosunetuzumab in 1 ml. Mosunetuzumab is a bispecific CD20-directed CD3 T-cell engager used to treat certain types of cancer.
Indications:

• Relapsed or Refractory Follicular Lymphoma (FL): Treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.

Instructions:

1. Administration: Administered as an intravenous infusion under the supervision of a healthcare professional qualified in the use of anti-cancer therapies.
2. Dosage: The recommended dosage is as follows:
   • Cycle 1: Day 1 – 1 mg, Day 8 – 2 mg, Day 15 – 60 mg.
   • Cycle 2: Day 1 – 60 mg.
   • Cycle 3 and beyond: Day 1 – 30 mg.
3. Timing: Take it at the same time each day to help you remember.
4. Monitoring: Regular monitoring of blood counts and other parameters is essential.